Coherus BioSciences Appoints Darlene Horton, M.D., Chief Medical and Regulatory Affairs Officer

On January 2, 2019 Coherus BioSciences, Inc. (Nasdaq: CHRS), reported the addition of Darlene Horton, M.D. as Chief Medical and Regulatory Affairs Officer (Press release, Coherus Biosciences, JAN 2, 2019, View Source [SID1234532391]). She assumed her role on January 1, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased that Dr. Horton has joined the executive team at Coherus," said Denny Lanfear, Chairman, President and CEO of Coherus. "She is a foremost biotechnology leader and clinician with an exceptional track record of delivering value to patients and shareholders."

"I believe there is a significant opportunity to accelerate the development and commercialization of biosimilar products. Coherus is leading the way in expanding access to life-changing biologic medicines while also significantly reducing costs to our healthcare system," said Darlene Horton, M.D. "I am honored to be joining Denny and the team at this exciting time for the company."

Dr. Horton recently was Chief Executive Officer of TulangCo, Inc., and Chief Medical Officer at SMC Biotechnology. Previously, she was President and Chief Executive Officer of Nile Therapeutics, Inc., and Vice President and Co-Chair, Joint Steering Committee between Itero and Allergan, and Co-Founder and Chief Medical Officer of Itero Biopharmaceuticals. Prior to that, she was Chief Medical Officer, Clinical Research and Medical Affairs, Senior Vice President, Clinical Research and Member of Corporate Executive Team at Scios, Inc. (a Johnson & Johnson company), where she also was Head, CV Therapeutic Area Center of Excellence.

Darlene earned her B.S. with Honors in Microbiology, and Doctor of Medicine from University of Florida. She did her internship and residency in the Department of Pediatrics at UCSF, and her Pediatric Cardiology Fellowship at the CV Research Institute of UCSF. She worked as a UCSF Clinical Faculty member in Pediatric Cardiology for 20 years, as a Staff Pediatrician at St. Luke’s Hospital and in the Intensive Care Nursery at Kaiser Hospital in San Francisco, California.

Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2019 Coherus BioSciences, Inc. (Nasdaq: CHRS), reported that senior management will present at the 37th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco (Press release, Coherus Biosciences, JAN 2, 2019, View Source [SID1234532390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at View Source

Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, reported that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9th at 8:00 a.m. PST/ 11:00 a.m. EST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will provide a corporate update at the conference (Press release, Mirati, JAN 2, 2019, View Source [SID1234532381]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and made available through the "Investors" section of www.mirati.com, and replays will be made available for 90 days following the events.

Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2019 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, JAN 2, 2019, View Source [SID1234532373]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, January 9, 2019
Time: 2:30 p.m. Pacific Standard Time
Location: Westin St. Francis Hotel, San Francisco
Webcast:

View Source

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

Alkermes’ Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference

On January 2, 2018 Alkermes plc (Nasdaq: ALKS) reported that its corporate presentation will be webcast live at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 at 9:30 a.m. PT (12:30 p.m. ET/5:30 p.m. GMT) from the Westin St. Francis Hotel in San Francisco (Press release, Alkermes, JAN 2, 2019, View Source;p=RssLanding&cat=news&id=2381873 [SID1234532371]). The presentation will be followed by a question and answer session that will begin at 10:00 a.m. PT (1:00 p.m. ET/6:00 p.m. GMT). A webcast of both the presentation and question and answer session may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com